Survodutide

Survodutide is a 29-amino-acid peptide developed for weight loss and treatment of MASH.

Survodutide acts as a dual GLP-1 and glucagon receptor agonist, targeting both receptors simultaneously. [Source: Peptide Dosing Protocols]

Survodutide acts on two targets at the same time: the GLP-1 receptor and the glucagon receptor. That is why it is grouped with newer obesity peptides like tirzepatide and retatrutide, but it is not the same as either one.

In plain English: GLP-1 may lower appetite and slow how fast food leaves the stomach. Glucagon may raise energy use, meaning the body may burn more calories at rest. Glucagon also acts in the liver, which is why Survodutide is being studied for MASH.

In research papers, Survodutide is called a dual agonist because one peptide molecule turns on both receptors. It also has a fatty-acid tail, similar to semaglutide, which helps it last long enough for once-weekly dosing.

Lowers appetite (GLP-1 arm): In Phase 2, around 16.6% of Survodutide participants reported decreased appetite vs 3.4% on placebo.

Raises energy expenditure (glucagon arm): Preclinical work showed Survodutide raised energy use in animal models and lowered liver fat.

Targets liver tissue: Glucagon receptors are common in the liver, which is why Survodutide is also being tested in MASH and MASH-cirrhosis trials. [Source: Peptide Dosing Protocols]

Provider notes: [PDP compound] survodutide